Summit Therapeutics PLC (SMMT) Stock Analysis

Summit Therapeutics PLC (SMMT) is a publicly traded company in the HEALTHCARE sector. It trades at $14.86, carries a market capitalization of $12.19B. This page summarizes the public market data, fundamentals, and frequently asked questions for SMMT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Summit Therapeutics PLC currently has a Neutral sentiment score of 0.05.

About Summit Therapeutics PLC

Summit Therapeutics PLC is a biopharmaceutical company headquartered in Cambridge, Massachusetts, specializing in the discovery and development of innovative treatments for infectious diseases. Leveraging its proprietary drug development platforms, Summit focuses on addressing significant unmet medical needs across its strategic operations in the United States, Latin America, and Europe. The company is committed to advancing patient care by delivering transformative therapies that improve the...

GNG Research Analysis

GNG Research scores Summit Therapeutics PLC (SMMT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SMMT.

Frequently Asked Questions

Does SMMT pay dividends?

Summit Therapeutics PLC (SMMT) does not currently pay a regular dividend.

What is SMMT's market cap?

Summit Therapeutics PLC (SMMT) has a market capitalization of $12.19B with a current stock price of $14.86.